- Investing Ideas
- French Pharmaceuticals & Biotech Healthy high growth potential
French Pharmaceuticals & Biotech Healthy high growth potential
Results
3
Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.
3 companies
Adocia
Market Cap: €79.5m
A clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity.
ADOC
€4.06
7D
-0.9%
1Y
9.8%
DBV Technologies
Market Cap: €847.5m
A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.
DBV
€2.86
7D
2.9%
1Y
79.7%
ABIVAX Société Anonyme
Market Cap: €6.6b
A clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
ABVX
€83.30
7D
-2.9%
1Y
1,154.5%